{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:01:07Z","timestamp":1792598467130,"version":"4.5.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,2,5]],"date-time":"2018-02-05T00:00:00Z","timestamp":1517788800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,2,5]],"date-time":"2018-02-05T00:00:00Z","timestamp":1517788800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Sodium glucose cotransporter 2 (SGLT2) inhibitors, an antidiabetic drug, promotes urinary excretion of glucose by blocking its reabsorption in the renal proximal tubules. It is unclear whether SGLT2 inhibition could attenuate nonalcoholic steatohepatitis (NASH) and NASH-associated hepatocellular carcinoma. We examined the preventive effects of an SGLT2 inhibitor canagliflozin (CANA) in Western diet (WD)-fed melanocortin 4 receptor-deficient (MC4R-KO) mice, a mouse model of human NASH. An eight-week CANA treatment attenuated hepatic steatosis in WD-fed MC4R-KO mice, with increased epididymal fat mass without inflammatory changes. CANA treatment for 20 weeks inhibited the development of hepatic fibrosis in WD-fed MC4R-KO mice. After one year of CANA treatment, the number of liver tumors was significantly reduced in WD-fed MC4R-KO mice. In adipose tissue, CANA suppressed the ratio of oxidative to reduced forms of glutathiones (GSSG\/GSH) in WD-fed MC4R-KO mice. Treatment with GSH significantly attenuated the H<jats:sub>2<\/jats:sub>O<jats:sub>2<\/jats:sub>-induced upregulation of genes related to NADPH oxidase in 3T3-L1 adipocytes, and that of <jats:italic>Il6<\/jats:italic>, <jats:italic>Tgfb<\/jats:italic>, and <jats:italic>Pdgfb<\/jats:italic> in RAW264.7 cells. This study provides evidence that SGLT2 inhibitors represent the unique class of drugs that can attenuate or delay the onset of NASH and eventually hepatocellular carcinoma, at least partly, through \u201chealthy adipose expansion\u201d.<\/jats:p>","DOI":"10.1038\/s41598-018-19658-7","type":"journal-article","created":{"date-parts":[[2018,1,30]],"date-time":"2018-01-30T11:11:43Z","timestamp":1517310703000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":160,"title":["Canagliflozin, an SGLT2 inhibitor, attenuates the development of hepatocellular carcinoma in a mouse model of human NASH"],"prefix":"10.1038","volume":"8","author":[{"given":"Kumiko","family":"Shiba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoichiro","family":"Tsuchiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chikara","family":"Komiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasutaka","family":"Miyachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"Shimazu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9515-7622","authenticated-orcid":false,"given":"Shinobu","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi","family":"Ogasawara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Katoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiko","family":"Itoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayoshi","family":"Suganami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,2,5]]},"reference":[{"key":"19658_CR1","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1001\/jama.2015.5370","volume":"313","author":"ME Rinella","year":"2015","unstructured":"Rinella, M. E. Nonalcoholic fatty liver disease: a systematic review. JAMA 313, 2263\u20132273, https:\/\/doi.org\/10.1001\/jama.2015.5370 (2015).","journal-title":"JAMA"},{"key":"19658_CR2","doi-asserted-by":"publisher","first-page":"15080","DOI":"10.1038\/nrdp.2015.80","volume":"1","author":"EM Brunt","year":"2015","unstructured":"Brunt, E. M. et al. Nonalcoholic fatty liver disease. Nat Rev Dis Primers 1, 15080, https:\/\/doi.org\/10.1038\/nrdp.2015.80 (2015).","journal-title":"Nat Rev Dis Primers"},{"key":"19658_CR3","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1053\/jhep.2003.50193","volume":"37","author":"BA Neuschwander-Tetri","year":"2003","unstructured":"Neuschwander-Tetri, B. A. & Caldwell, S. H. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 37, 1202\u20131219, https:\/\/doi.org\/10.1053\/jhep.2003.50193 (2003).","journal-title":"Hepatology"},{"key":"19658_CR4","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s11894-008-0011-1","volume":"10","author":"W Dunn","year":"2008","unstructured":"Dunn, W. & Schwimmer, J. B. The obesity epidemic and nonalcoholic fatty liver disease in children. Curr Gastroenterol Rep 10, 67\u201372 (2008).","journal-title":"Curr Gastroenterol Rep"},{"key":"19658_CR5","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1016\/S0016-5085(99)70506-8","volume":"116","author":"CA Matteoni","year":"1999","unstructured":"Matteoni, C. A. et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 116, 1413\u20131419 (1999).","journal-title":"Gastroenterology"},{"key":"19658_CR6","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1056\/NEJMoa1008862","volume":"364","author":"C Emerging Risk Factors","year":"2011","unstructured":"Emerging Risk Factors, C. et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 364, 829\u2013841, https:\/\/doi.org\/10.1056\/NEJMoa1008862 (2011).","journal-title":"N Engl J Med"},{"key":"19658_CR7","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1056\/NEJMoa060326","volume":"355","author":"R Belfort","year":"2006","unstructured":"Belfort, R. et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 355, 2297\u20132307, https:\/\/doi.org\/10.1056\/NEJMoa060326 (2006).","journal-title":"N Engl J Med"},{"key":"19658_CR8","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","volume":"387","author":"MJ Armstrong","year":"2016","unstructured":"Armstrong, M. J. et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet 387, 679\u2013690, https:\/\/doi.org\/10.1016\/S0140-6736(15)00803-X (2016).","journal-title":"Lancet"},{"key":"19658_CR9","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1053\/j.gastro.2013.05.042","volume":"145","author":"S Mudaliar","year":"2013","unstructured":"Mudaliar, S. et al. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology 145, 574\u2013582 e571, https:\/\/doi.org\/10.1053\/j.gastro.2013.05.042 (2013).","journal-title":"Gastroenterology"},{"key":"19658_CR10","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","volume":"385","author":"BA Neuschwander-Tetri","year":"2015","unstructured":"Neuschwander-Tetri, B. A. et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 385, 956\u2013965, https:\/\/doi.org\/10.1016\/S0140-6736(14)61933-4 (2015).","journal-title":"Lancet"},{"key":"19658_CR11","doi-asserted-by":"publisher","first-page":"e0146337","DOI":"10.1371\/journal.pone.0146337","volume":"11","author":"Y Honda","year":"2016","unstructured":"Honda, Y. et al. The Selective SGLT2 Inhibitor Ipragliflozin Has a Therapeutic Effect on Nonalcoholic Steatohepatitis in Mice. PLoS One 11, e0146337, https:\/\/doi.org\/10.1371\/journal.pone.0146337 (2016).","journal-title":"PLoS One"},{"key":"19658_CR12","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1210\/en.2015-1588","volume":"157","author":"A Obata","year":"2016","unstructured":"Obata, A. et al. Tofogliflozin Improves Insulin Resistance in Skeletal Muscle and Accelerates Lipolysis in Adipose Tissue in Male Mice. Endocrinology 157, 1029\u20131042, https:\/\/doi.org\/10.1210\/en.2015-1588 (2016).","journal-title":"Endocrinology"},{"key":"19658_CR13","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.jceh.2015.02.005","volume":"5","author":"S Nakano","year":"2015","unstructured":"Nakano, S. et al. Remogliflozin Etabonate Improves Fatty Liver Disease in Diet-Induced Obese Male Mice. J Clin Exp Hepatol 5, 190\u2013198, https:\/\/doi.org\/10.1016\/j.jceh.2015.02.005 (2015).","journal-title":"J Clin Exp Hepatol"},{"key":"19658_CR14","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s13098-015-0102-8","volume":"7","author":"S Qiang","year":"2015","unstructured":"Qiang, S. et al. Treatment with the SGLT2 inhibitor luseogliflozin improves nonalcoholic steatohepatitis in a rodent model with diabetes mellitus. Diabetol Metab Syndr 7, 104, https:\/\/doi.org\/10.1186\/s13098-015-0102-8 (2015).","journal-title":"Diabetol Metab Syndr"},{"key":"19658_CR15","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.ejphar.2015.02.009","volume":"754","author":"Y Hayashizaki-Someya","year":"2015","unstructured":"Hayashizaki-Someya, Y. et al. Ipragliflozin, an SGLT2 inhibitor, exhibits a prophylactic effect on hepatic steatosis and fibrosis induced by choline-deficient l-amino acid-defined diet in rats. Eur J Pharmacol 754, 19\u201324, https:\/\/doi.org\/10.1016\/j.ejphar.2015.02.009 (2015).","journal-title":"Eur J Pharmacol"},{"key":"19658_CR16","doi-asserted-by":"publisher","first-page":"e0116851","DOI":"10.1371\/journal.pone.0116851","volume":"10","author":"Y Watanabe","year":"2015","unstructured":"Watanabe, Y. et al. Beneficial effects of canagliflozin in combination with pioglitazone on insulin sensitivity in rodent models of obese type 2 diabetes. PLoS One 10, e0116851, https:\/\/doi.org\/10.1371\/journal.pone.0116851 (2015).","journal-title":"PLoS One"},{"key":"19658_CR17","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.ejphar.2013.05.014","volume":"715","author":"A Tahara","year":"2013","unstructured":"Tahara, A. et al. Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice. Eur J Pharmacol 715, 246\u2013255, https:\/\/doi.org\/10.1016\/j.ejphar.2013.05.014 (2013).","journal-title":"Eur J Pharmacol"},{"key":"19658_CR18","doi-asserted-by":"publisher","first-page":"e0151511","DOI":"10.1371\/journal.pone.0151511","volume":"11","author":"C Komiya","year":"2016","unstructured":"Komiya, C. et al. Ipragliflozin Improves Hepatic Steatosis in Obese Mice and Liver Dysfunction in Type 2 Diabetic Patients Irrespective of Body Weight Reduction. PLoS One 11, e0151511, https:\/\/doi.org\/10.1371\/journal.pone.0151511 (2016).","journal-title":"PLoS One"},{"key":"19658_CR19","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.1016\/j.ajpath.2011.07.014","volume":"179","author":"M Itoh","year":"2011","unstructured":"Itoh, M. et al. Melanocortin 4 receptor-deficient mice as a novel mouse model of nonalcoholic steatohepatitis. Am J Pathol 179, 2454\u20132463, https:\/\/doi.org\/10.1016\/j.ajpath.2011.07.014 (2011).","journal-title":"Am J Pathol"},{"key":"19658_CR20","doi-asserted-by":"publisher","first-page":"e30555","DOI":"10.1371\/journal.pone.0030555","volume":"7","author":"Y Liang","year":"2012","unstructured":"Liang, Y. et al. Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models. PLoS One 7, e30555, https:\/\/doi.org\/10.1371\/journal.pone.0030555 (2012).","journal-title":"PLoS One"},{"key":"19658_CR21","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.cell.2005.08.035","volume":"123","author":"N Balthasar","year":"2005","unstructured":"Balthasar, N. et al. Divergence of melanocortin pathways in the control of food intake and energy expenditure. Cell 123, 493\u2013505, https:\/\/doi.org\/10.1016\/j.cell.2005.08.035 (2005).","journal-title":"Cell"},{"key":"19658_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms5982","volume":"5","author":"M Tanaka","year":"2014","unstructured":"Tanaka, M. et al. Macrophage-inducible C-type lectin underlies obesity-induced adipose tissue fibrosis. Nature communications 5, 4982, https:\/\/doi.org\/10.1038\/ncomms5982 (2014).","journal-title":"Nature communications"},{"key":"19658_CR23","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1172\/JCI114142","volume":"84","author":"LC Groop","year":"1989","unstructured":"Groop, L. C. et al. Glucose and free fatty acid metabolism in non-insulin-dependent diabetes mellitus. Evidence for multiple sites of insulin resistance. J Clin Invest 84, 205\u2013213, https:\/\/doi.org\/10.1172\/JCI114142 (1989).","journal-title":"J Clin Invest"},{"key":"19658_CR24","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1210\/jc.2017-00047","volume":"102","author":"E Sondergaard","year":"2017","unstructured":"Sondergaard, E., Espinosa De Ycaza, A. E., Morgan-Bathke, M. & Jensen, M. D. How to Measure Adipose Tissue Insulin Sensitivity. J Clin Endocrinol Metab 102, 1193\u20131199, https:\/\/doi.org\/10.1210\/jc.2017-00047 (2017).","journal-title":"J Clin Endocrinol Metab"},{"key":"19658_CR25","doi-asserted-by":"publisher","first-page":"e82163","DOI":"10.1371\/journal.pone.0082163","volume":"8","author":"M Itoh","year":"2013","unstructured":"Itoh, M. et al. Hepatic crown-like structure: a unique histological feature in non-alcoholic steatohepatitis in mice and humans. PLoS One 8, e82163, https:\/\/doi.org\/10.1371\/journal.pone.0082163 (2013).","journal-title":"PLoS One"},{"key":"19658_CR26","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.1194\/jlr.M500294-JLR200","volume":"46","author":"S Cinti","year":"2005","unstructured":"Cinti, S. et al. Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans. J Lipid Res 46, 2347\u20132355, https:\/\/doi.org\/10.1194\/jlr.M500294-JLR200 (2005).","journal-title":"J Lipid Res"},{"key":"19658_CR27","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1056\/NEJMra1011035","volume":"371","author":"GI Shulman","year":"2014","unstructured":"Shulman, G. I. Ectopic fat in insulin resistance, dyslipidemia, and cardiometabolic disease. N Engl J Med 371, 1131\u20131141, https:\/\/doi.org\/10.1056\/NEJMra1011035 (2014).","journal-title":"N Engl J Med"},{"key":"19658_CR28","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1093\/jn\/134.3.489","volume":"134","author":"G Wu","year":"2004","unstructured":"Wu, G., Fang, Y. Z., Yang, S., Lupton, J. R. & Turner, N. D. Glutathione metabolism and its implications for health. The Journal of nutrition 134, 489\u2013492 (2004).","journal-title":"The Journal of nutrition"},{"key":"19658_CR29","doi-asserted-by":"publisher","first-page":"E1326","DOI":"10.1152\/ajpendo.90921.2008","volume":"296","author":"H Kobayashi","year":"2009","unstructured":"Kobayashi, H., Matsuda, M., Fukuhara, A., Komuro, R. & Shimomura, I. Dysregulated glutathione metabolism links to impaired insulin action in adipocytes. Am J Physiol Endocrinol Metab 296, E1326\u20131334, https:\/\/doi.org\/10.1152\/ajpendo.90921.2008 (2009).","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"19658_CR30","doi-asserted-by":"publisher","unstructured":"Seko, Y. et al. Effects of canagliflozin, an SGLT2 inhibitor, on hepatic function in Japanese patients with type 2 diabetes mellitus: pooled and subgroup analyses of clinical trials. J Gastroenterol, https:\/\/doi.org\/10.1007\/s00535-017-1364-8 (2017).","DOI":"10.1007\/s00535-017-1364-8"},{"key":"19658_CR31","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1111\/dom.12054","volume":"15","author":"K Stenlof","year":"2013","unstructured":"Stenlof, K. et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab 15, 372\u2013382, https:\/\/doi.org\/10.1111\/dom.12054 (2013).","journal-title":"Diabetes Obes Metab"},{"key":"19658_CR32","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1016\/S0140-6736(10)60407-2","volume":"375","author":"CJ Bailey","year":"2010","unstructured":"Bailey, C. J., Gross, J. L., Pieters, A., Bastien, A. & List, J. F. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet 375, 2223\u20132233, https:\/\/doi.org\/10.1016\/S0140-6736(10)60407-2 (2010).","journal-title":"Lancet"},{"key":"19658_CR33","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.2337\/dc15-0355","volume":"38","author":"G Ferrannini","year":"2015","unstructured":"Ferrannini, G. et al. Energy Balance After Sodium-Glucose Cotransporter 2 Inhibition. Diabetes Care 38, 1730\u20131735, https:\/\/doi.org\/10.2337\/dc15-0355 (2015).","journal-title":"Diabetes Care"},{"key":"19658_CR34","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1126\/science.1204265","volume":"332","author":"JC Cohen","year":"2011","unstructured":"Cohen, J. C., Horton, J. D. & Hobbs, H. H. Human fatty liver disease: old questions and new insights. Science 332, 1519\u20131523, https:\/\/doi.org\/10.1126\/science.1204265 (2011).","journal-title":"Science"},{"key":"19658_CR35","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1161\/ATVBAHA.114.303034","volume":"34","author":"CD Byrne","year":"2014","unstructured":"Byrne, C. D. & Targher, G. Ectopic fat, insulin resistance, and nonalcoholic fatty liver disease: implications for cardiovascular disease. Arterioscler Thromb Vasc Biol 34, 1155\u20131161, https:\/\/doi.org\/10.1161\/ATVBAHA.114.303034 (2014).","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"19658_CR36","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1038\/nrd.2016.75","volume":"15","author":"CM Kusminski","year":"2016","unstructured":"Kusminski, C. M., Bickel, P. E. & Scherer, P. E. Targeting adipose tissue in the treatment of obesity-associated diabetes. Nat Rev Drug Discov 15, 639\u2013660, https:\/\/doi.org\/10.1038\/nrd.2016.75 (2016).","journal-title":"Nat Rev Drug Discov"},{"key":"19658_CR37","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1038\/nrm4074","volume":"16","author":"Y Wang","year":"2015","unstructured":"Wang, Y., Viscarra, J., Kim, S. J. & Sul, H. S. Transcriptional regulation of hepatic lipogenesis. Nat Rev Mol Cell Biol 16, 678\u2013689, https:\/\/doi.org\/10.1038\/nrm4074 (2015).","journal-title":"Nat Rev Mol Cell Biol"},{"key":"19658_CR38","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.cmet.2007.12.009","volume":"7","author":"MS Brown","year":"2008","unstructured":"Brown, M. S. & Goldstein, J. L. Selective versus total insulin resistance: a pathogenic paradox. Cell Metab 7, 95\u201396, https:\/\/doi.org\/10.1016\/j.cmet.2007.12.009 (2008).","journal-title":"Cell Metab"},{"key":"19658_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms8906","volume":"6","author":"TS Morley","year":"2015","unstructured":"Morley, T. S., Xia, J. Y. & Scherer, P. E. Selective enhancement of insulin sensitivity in the mature adipocyte is sufficient for systemic metabolic improvements. Nature communications 6, 7906, https:\/\/doi.org\/10.1038\/ncomms8906 (2015).","journal-title":"Nature communications"},{"key":"19658_CR40","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1128\/MCB.01300-08","volume":"29","author":"T Khan","year":"2009","unstructured":"Khan, T. et al. Metabolic dysregulation and adipose tissue fibrosis: role of collagen VI. Mol Cell Biol 29, 1575\u20131591, https:\/\/doi.org\/10.1128\/MCB.01300-08 (2009).","journal-title":"Mol Cell Biol"},{"key":"19658_CR41","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1038\/sj.ki.5002033","volume":"71","author":"N Takahashi","year":"2007","unstructured":"Takahashi, N., Boysen, G., Li, F., Li, Y. & Swenberg, J. A. Tandem mass spectrometry measurements of creatinine in mouse plasma and urine for determining glomerular filtration rate. Kidney Int 71, 266\u2013271, https:\/\/doi.org\/10.1038\/sj.ki.5002033 (2007).","journal-title":"Kidney Int"},{"key":"19658_CR42","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1172\/JCI72227","volume":"124","author":"E Ferrannini","year":"2014","unstructured":"Ferrannini, E. et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest 124, 499\u2013508, https:\/\/doi.org\/10.1172\/JCI72227 (2014).","journal-title":"J Clin Invest"},{"key":"19658_CR43","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1172\/JCI70704","volume":"124","author":"A Merovci","year":"2014","unstructured":"Merovci, A. et al. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest 124, 509\u2013514, https:\/\/doi.org\/10.1172\/JCI70704 (2014).","journal-title":"J Clin Invest"},{"key":"19658_CR44","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1159\/000264397","volume":"63","author":"TH Moran","year":"2010","unstructured":"Moran, T. H. Hypothalamic nutrient sensing and energy balance. Forum Nutr 63, 94\u2013101, https:\/\/doi.org\/10.1159\/000264397 (2010).","journal-title":"Forum Nutr"},{"key":"19658_CR45","doi-asserted-by":"publisher","first-page":"4617","DOI":"10.1074\/jbc.M411863200","volume":"280","author":"Y Lin","year":"2005","unstructured":"Lin, Y. et al. The hyperglycemia-induced inflammatory response in adipocytes: the role of reactive oxygen species. J Biol Chem 280, 4617\u20134626, https:\/\/doi.org\/10.1074\/jbc.M411863200 (2005).","journal-title":"J Biol Chem"},{"key":"19658_CR46","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.metabol.2006.01.003","volume":"55","author":"MC Bravi","year":"2006","unstructured":"Bravi, M. C. et al. Insulin decreases intracellular oxidative stress in patients with type 2 diabetes mellitus. Metabolism 55, 691\u2013695, https:\/\/doi.org\/10.1016\/j.metabol.2006.01.003 (2006).","journal-title":"Metabolism"},{"key":"19658_CR47","first-page":"483","volume":"52","author":"SI Rizvi","year":"2001","unstructured":"Rizvi, S. I. & Zaid, M. A. Intracellular reduced glutathione content in normal and type 2 diabetic erythrocytes: effect of insulin and (-)epicatechin. J Physiol Pharmacol 52, 483\u2013488 (2001).","journal-title":"J Physiol Pharmacol"},{"key":"19658_CR48","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1172\/JCI21625","volume":"114","author":"S Furukawa","year":"2004","unstructured":"Furukawa, S. et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 114, 1752\u20131761, https:\/\/doi.org\/10.1172\/JCI21625 (2004).","journal-title":"J Clin Invest"},{"key":"19658_CR49","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.1002\/jcp.22542","volume":"226","author":"P Vigilanza","year":"2011","unstructured":"Vigilanza, P., Aquilano, K., Baldelli, S., Rotilio, G. & Ciriolo, M. R. Modulation of intracellular glutathione affects adipogenesis in 3T3-L1 cells. J Cell Physiol 226, 2016\u20132024, https:\/\/doi.org\/10.1002\/jcp.22542 (2011).","journal-title":"J Cell Physiol"},{"key":"19658_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/srep13091","volume":"5","author":"D Lettieri Barbato","year":"2015","unstructured":"Lettieri Barbato, D. et al. Glutathione Decrement Drives Thermogenic Program In Adipose Cells. Scientific reports 5, 13091, https:\/\/doi.org\/10.1038\/srep13091 (2015).","journal-title":"Scientific reports"},{"key":"19658_CR51","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1002\/hep.25782","volume":"56","author":"D Kawai","year":"2012","unstructured":"Kawai, D. et al. Hydrogen-rich water prevents progression of nonalcoholic steatohepatitis and accompanying hepatocarcinogenesis in mice. Hepatology 56, 912\u2013921, https:\/\/doi.org\/10.1002\/hep.25782 (2012).","journal-title":"Hepatology"},{"key":"19658_CR52","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1002\/hep.20012","volume":"39","author":"K Promrat","year":"2004","unstructured":"Promrat, K. et al. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology 39, 188\u2013196, https:\/\/doi.org\/10.1002\/hep.20012 (2004).","journal-title":"Hepatology"},{"key":"19658_CR53","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/nrgastro.2016.147","volume":"14","author":"H Tilg","year":"2017","unstructured":"Tilg, H., Moschen, A. R. & Roden, M. NAFLD and diabetes mellitus. Nature reviews. Gastroenterology & hepatology 14, 32\u201342, https:\/\/doi.org\/10.1038\/nrgastro.2016.147 (2017).","journal-title":"Gastroenterology & hepatology"},{"key":"19658_CR54","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1146\/annurev-physiol-021115-105331","volume":"78","author":"JT Haas","year":"2016","unstructured":"Haas, J. T., Francque, S. & Staels, B. Pathophysiology and Mechanisms of Nonalcoholic Fatty Liver Disease. Annu Rev Physiol 78, 181\u2013205, https:\/\/doi.org\/10.1146\/annurev-physiol-021115-105331 (2016).","journal-title":"Annu Rev Physiol"},{"key":"19658_CR55","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1586\/17474124.2016.1110018","volume":"10","author":"P Dongiovanni","year":"2016","unstructured":"Dongiovanni, P., Rametta, R., Meroni, M. & Valenti, L. The role of insulin resistance in nonalcoholic steatohepatitis and liver disease development\u2013a potential therapeutic target? Expert Rev Gastroenterol Hepatol 10, 229\u2013242, https:\/\/doi.org\/10.1586\/17474124.2016.1110018 (2016).","journal-title":"Expert Rev Gastroenterol Hepatol"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-19658-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-19658-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-19658-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T01:57:55Z","timestamp":1671587875000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-19658-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,5]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["19658"],"URL":"https:\/\/doi.org\/10.1038\/s41598-018-19658-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,5]]},"assertion":[{"value":"22 August 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.I. is the recipient of research funding from Shionogi & Co., Ltd.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"2362"}}